XML 214 R2.htm IDEA: XBRL DOCUMENT
v3.24.1

Pay vs Performance Disclosure - USD ($) | 12 Months Ended
--- | ---
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Pay vs Performance Disclosure [Table] |  |  |  |  |
Pay vs Performance [Table Text Block] |  | ## Pay Versus Performance As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive “compensation actually paid” and certain financial performance of the Company. For further information regarding our pay for performance philosophy and how we align executive compensation with the Company’s performance, refer to the “Compensation Discussion and Analysis” on page 45.
|  |  |  |  |  |  |  |  |  |  |  |  |  | Value of Initial Fixed $100 Investment Based on: |  |  |  |  |  |  |
Year |  | Summary Compensation Table Total for Mr. O’Day(1) |  |  | Compensation Actually Paid to Mr. O’Day(2) |  |  | Average Summary Compensation Table Total for Other NEOs(3) |  |  | Average Compensation Actually Paid to Other NEOs(4) |  |  | Total Shareholder Return(5) |  |  | Peer Group Total Shareholder Return(6) |  |  | Net Income (in millions)(7) |  |  | Net Product Revenue (in millions)(8) |
2023 |  | $ | 22,607,690 |  |  | $ | 15,483,783 |  |  | $ | 7,588,163 |  |  | $ | 5,469,137 |  |  | $ | 147 |  |  | $ | 119 |  |  | $ | 5,613 |  |  | $ | 26,934 |
2022 |  | $ | 21,621,253 |  |  | $ | 54,965,255 |  |  | $ | 7,874,828 |  |  | $ | 18,182,586 |  |  | $ | 150 |  |  | $ | 114 |  |  | $ | 4,566 |  |  | $ | 26,982 |
2021 |  | $ | 19,229,466 |  |  | $ | 31,485,348 |  |  | $ | 6,279,776 |  |  | $ | 9,693,178 |  |  | $ | 121 |  |  | $ | 126 |  |  | $ | 6,201 |  |  | $ | 27,008 |
2020 |  | $ | 18,998,095 |  |  | $ | 16,117,322 |  |  | $ | 6,616,768 |  |  | $ | 6,126,435 |  |  | $ | 93 |  |  | $ | 126 |  |  | $ | 89 |  |  | $ | 24,355 |
(1) | The dollar amounts reported are the amounts reported in the “Total” column of the Summary Compensation Table for our Chairman and Chief Executive Officer, Mr. O’Day.
(2) | The dollar amounts reported represent the amount of “compensation actually paid”, as computed in accordance with SEC rules, for Mr. O’Day. The dollar amounts do not reflect the actual amount of compensation earned by or paid during the applicable year. In accordance with SEC rules, the following adjustments were made to total compensation to determine the compensation actually paid:
(3) | The dollar amounts reported represent the average of the amounts reported for our NEOs as a group (excluding our CEO) in the “Total” column of the Summary Compensation Table in each applicable year. The NEOs included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2023 and 2022, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Deborah H. Telman; and (ii) for 2021 and 2020, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Brett A. Pletcher.
(4) | The dollar amounts reported represent the average amount of “compensation actually paid” to the NEOs identified in footnote 3, as computed in accordance with SEC rules. The dollar amounts do not reflect the actual amount of compensation earned by or paid to the any NEO during the applicable year. In accordance with the SEC rules, the following adjustments were made to average total compensation for the NEOs for each year to determine the compensation actually paid:
(5) | Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end of each year shown and the beginning of the measurement period by our share price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is December 31, 2019.
(6) | The peer group used for this purpose is Nasdaq Biotechnology Index.
(7) | The dollar amounts reported represent the amount of net income reflected in our Consolidated Statements of Income included in our Annual Report on Form 10-K for the applicable year. Included in our net income for 2020 was a $4.5 billion charge to acquired in-process research and development (“IPR&D”) expense recorded in connection with our acquisition of Forty Seven, Inc. Our 2022 net income included a $2.7 billion partial impairment charge related to certain IPR&D assets acquired from Immunomedics, Inc.
(8) | The dollar amounts reported represent the amount of net product sales revenue reflected in our Consolidated Statements of Income included in our Annual Report on Form 10-K for the applicable year. Total full year 2023 product sales of $26.9 billion were relatively flat compared to the same period in 2022, with lower Veklury sales largely offset by higher HIV and Oncology sales. Total product sales, excluding Veklury, increased 7% to $24.7 billion in the full year 2023 compared to 2022, primarily driven by higher HIV and Oncology sales.
(1) | The dollar amounts reported are the amounts reported in the “Total” column of the Summary Compensation Table for our Chairman and Chief Executive Officer, Mr. O’Day.
(2) | The dollar amounts reported represent the amount of “compensation actually paid”, as computed in accordance with SEC rules, for Mr. O’Day. The dollar amounts do not reflect the actual amount of compensation earned by or paid during the applicable year. In accordance with SEC rules, the following adjustments were made to total compensation to determine the compensation actually paid:
| Year |  | Summary Compensation Table Total for Mr. O’Day |  |  | Less: Summary Compensation Table Reported Value of Equity Awards(a) |  |  | Plus: Equity Award Adjustments(b) |  |  | Equals: Compensation Actually Paid to Mr. O’Day |
| 2023 |  | $ | 22,607,690 |  |  | $ | 15,615,056 |  |  | $ | 8,491,149 |  |  | $ | 15,483,783 |
| 2022 |  | $ | 21,621,253 |  |  | $ | 14,353,915 |  |  | $ | 47,697,917 |  |  | $ | 54,965,255 |
| 2021 |  | $ | 19,229,466 |  |  | $ | 13,139,064 |  |  | $ | 25,394,946 |  |  | $ | 31,485,348 |
| 2020 |  | $ | 18,998,095 |  |  | $ | 11,513,097 |  |  | $ | 8,632,324 |  |  | $ | 16,117,322 |
| (a) | Represents the aggregate grant-date fair value of equity awards as reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year.
| (b) | The equity award adjustments for each applicable year were as set forth in the table below. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows:
| Year |  | Year End Fair Value of Equity Awards Granted during the Year |  |  | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years |  |  | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year |  |  | Value of Dividend Equivalents Accrued or other Earnings Paid on Stock Awards not Otherwise Reflected in Fair Value |  |  | Total Equity Award Adjustments |
| 2023 |  | $ | 12,525,814 |  |  | $ | (2,481,113) |  |  | $ | (2,859,625) |  |  | $ | 1,306,073 |  |  | $ | 8,491,149 |
| 2022 |  | $ | 34,153,918 |  |  | $ | 14,183,571 |  |  | $ | (1,966,582) |  |  | $ | 1,327,010 |  |  | $ | 47,697,917 |
| 2021 |  | $ | 17,162,219 |  |  | $ | 6,011,125 |  |  | $ | 707,262 |  |  | $ | 1,514,340 |  |  | $ | 25,394,946 |
| 2020 |  | $ | 8,885,442 |  |  | $ | (1,693,496) |  |  | $ | 409,911 |  |  | $ | 1,030,467 |  |  | $ | 8,632,324 |
(3) | The dollar amounts reported represent the average of the amounts reported for our NEOs as a group (excluding our CEO) in the “Total” column of the Summary Compensation Table in each applicable year. The NEOs included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2023 and 2022, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Deborah H. Telman; and (ii) for 2021 and 2020, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Brett A. Pletcher.
(4) | The dollar amounts reported represent the average amount of “compensation actually paid” to the NEOs identified in footnote 3, as computed in accordance with SEC rules. The dollar amounts do not reflect the actual amount of compensation earned by or paid to the any NEO during the applicable year. In accordance with the SEC rules, the following adjustments were made to average total compensation for the NEOs for each year to determine the compensation actually paid:
| Year |  | Average Reported Summary Compensation Table Total for Other NEOs |  |  | Less: Summary Compensation Table Average Reported Value of Equity Awards |  |  | Plus: Average Equity Award Adjustments(a) |  |  | Equals: Average Compensation Actually Paid to Other NEOs |
| 2023 |  | $ | 7,588,163 |  |  | $ | 4,809,225 |  |  | $ | 2,690,199 |  |  | $ | 5,469,137 |
| 2022 |  | $ | 7,874,828 |  |  | $ | 4,961,052 |  |  | $ | 15,268,810 |  |  | $ | 18,182,586 |
| 2021 |  | $ | 6,279,776 |  |  | $ | 3,625,534 |  |  | $ | 7,038,936 |  |  | $ | 9,693,178 |
| 2020 |  | $ | 6,616,768 |  |  | $ | 3,087,064 |  |  | $ | 2,596,731 |  |  | $ | 6,126,435 |
| (a) | The amounts deducted or added in calculating the total average equity award adjustments are as follows:
| Year |  | Average Year End Fair Value of Equity Awards Granted during the Year |  |  | Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years |  |  | Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year |  |  | Average Value of Dividend Equivalents Accrued or other Earnings Paid on Stock Awards not Otherwise Reflected in Fair Value |  |  | Total Average Equity Award Adjustments |
| 2023 |  | $ | 3,955,902 |  |  | $ | (789,322) |  |  | $ | (879,498) |  |  | $ | 403,117 |  |  | $ | 2,690,199 |
| 2022 |  | $ | 11,751,514 |  |  | $ | 3,365,229 |  |  | $ | (289,102) |  |  | $ | 441,169 |  |  | $ | 15,268,810 |
| 2021 |  | $ | 4,989,853 |  |  | $ | 1,461,574 |  |  | $ | 271,571 |  |  | $ | 315,938 |  |  | $ | 7,038,936 |
| 2020 |  | $ | 2,488,166 |  |  | $ | (365,446) |  |  | $ | 269,145 |  |  | $ | 204,866 |  |  | $ | 2,596,731 |
(5) | Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end of each year shown and the beginning of the measurement period by our share price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is December 31, 2019.
(6) | The peer group used for this purpose is Nasdaq Biotechnology Index.
(7) | The dollar amounts reported represent the amount of net income reflected in our Consolidated Statements of Income included in our Annual Report on Form 10-K for the applicable year. Included in our net income for 2020 was a $4.5 billion charge to acquired in-process research and development (“IPR&D”) expense recorded in connection with our acquisition of Forty Seven, Inc. Our 2022 net income included a $2.7 billion partial impairment charge related to certain IPR&D assets acquired from Immunomedics, Inc.
(8) | The dollar amounts reported represent the amount of net product sales revenue reflected in our Consolidated Statements of Income included in our Annual Report on Form 10-K for the applicable year. Total full year 2023 product sales of $26.9 billion were relatively flat compared to the same period in 2022, with lower Veklury sales largely offset by higher HIV and Oncology sales. Total product sales, excluding Veklury, increased 7% to $24.7 billion in the full year 2023 compared to 2022, primarily driven by higher HIV and Oncology sales.
Company Selected Measure Name |  | Net Product Revenue |  |  |
Named Executive Officers, Footnote [Text Block] |  |
(1) | The dollar amounts reported are the amounts reported in the “Total” column of the Summary Compensation Table for our Chairman and Chief Executive Officer, Mr. O’Day.
(3) | The dollar amounts reported represent the average of the amounts reported for our NEOs as a group (excluding our CEO) in the “Total” column of the Summary Compensation Table in each applicable year. The NEOs included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2023 and 2022, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Deborah H. Telman; and (ii) for 2021 and 2020, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Brett A. Pletcher.
Peer Group Issuers, Footnote [Text Block] |  |
(6) | The peer group used for this purpose is Nasdaq Biotechnology Index.
Adjustment To PEO Compensation, Footnote [Text Block] |  |
(2) | The dollar amounts reported represent the amount of “compensation actually paid”, as computed in accordance with SEC rules, for Mr. O’Day. The dollar amounts do not reflect the actual amount of compensation earned by or paid during the applicable year. In accordance with SEC rules, the following adjustments were made to total compensation to determine the compensation actually paid:
| Year |  | Summary Compensation Table Total for Mr. O’Day |  |  | Less: Summary Compensation Table Reported Value of Equity Awards(a) |  |  | Plus: Equity Award Adjustments(b) |  |  | Equals: Compensation Actually Paid to Mr. O’Day |
| 2023 |  | $ | 22,607,690 |  |  | $ | 15,615,056 |  |  | $ | 8,491,149 |  |  | $ | 15,483,783 |
| 2022 |  | $ | 21,621,253 |  |  | $ | 14,353,915 |  |  | $ | 47,697,917 |  |  | $ | 54,965,255 |
| 2021 |  | $ | 19,229,466 |  |  | $ | 13,139,064 |  |  | $ | 25,394,946 |  |  | $ | 31,485,348 |
| 2020 |  | $ | 18,998,095 |  |  | $ | 11,513,097 |  |  | $ | 8,632,324 |  |  | $ | 16,117,322 |
| (a) | Represents the aggregate grant-date fair value of equity awards as reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year.
| (b) | The equity award adjustments for each applicable year were as set forth in the table below. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows:
| Year |  | Year End Fair Value of Equity Awards Granted during the Year |  |  | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years |  |  | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year |  |  | Value of Dividend Equivalents Accrued or other Earnings Paid on Stock Awards not Otherwise Reflected in Fair Value |  |  | Total Equity Award Adjustments |
| 2023 |  | $ | 12,525,814 |  |  | $ | (2,481,113) |  |  | $ | (2,859,625) |  |  | $ | 1,306,073 |  |  | $ | 8,491,149 |
| 2022 |  | $ | 34,153,918 |  |  | $ | 14,183,571 |  |  | $ | (1,966,582) |  |  | $ | 1,327,010 |  |  | $ | 47,697,917 |
| 2021 |  | $ | 17,162,219 |  |  | $ | 6,011,125 |  |  | $ | 707,262 |  |  | $ | 1,514,340 |  |  | $ | 25,394,946 |
| 2020 |  | $ | 8,885,442 |  |  | $ | (1,693,496) |  |  | $ | 409,911 |  |  | $ | 1,030,467 |  |  | $ | 8,632,324 |
Non-PEO NEO Average Total Compensation Amount | [1] | $ 7,588,163 | $ 7,874,828 | $ 6,279,776 | $ 6,616,768
Non-PEO NEO Average Compensation Actually Paid Amount | [2] | $ 5,469,137 | 18,182,586 | 9,693,178 | 6,126,435
Adjustment to Non-PEO NEO Compensation Footnote [Text Block] |  |
(4) | The dollar amounts reported represent the average amount of “compensation actually paid” to the NEOs identified in footnote 3, as computed in accordance with SEC rules. The dollar amounts do not reflect the actual amount of compensation earned by or paid to the any NEO during the applicable year. In accordance with the SEC rules, the following adjustments were made to average total compensation for the NEOs for each year to determine the compensation actually paid:
| Year |  | Average Reported Summary Compensation Table Total for Other NEOs |  |  | Less: Summary Compensation Table Average Reported Value of Equity Awards |  |  | Plus: Average Equity Award Adjustments(a) |  |  | Equals: Average Compensation Actually Paid to Other NEOs |
| 2023 |  | $ | 7,588,163 |  |  | $ | 4,809,225 |  |  | $ | 2,690,199 |  |  | $ | 5,469,137 |
| 2022 |  | $ | 7,874,828 |  |  | $ | 4,961,052 |  |  | $ | 15,268,810 |  |  | $ | 18,182,586 |
| 2021 |  | $ | 6,279,776 |  |  | $ | 3,625,534 |  |  | $ | 7,038,936 |  |  | $ | 9,693,178 |
| 2020 |  | $ | 6,616,768 |  |  | $ | 3,087,064 |  |  | $ | 2,596,731 |  |  | $ | 6,126,435 |
| (a) | The amounts deducted or added in calculating the total average equity award adjustments are as follows:
| Year |  | Average Year End Fair Value of Equity Awards Granted during the Year |  |  | Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years |  |  | Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year |  |  | Average Value of Dividend Equivalents Accrued or other Earnings Paid on Stock Awards not Otherwise Reflected in Fair Value |  |  | Total Average Equity Award Adjustments |
| 2023 |  | $ | 3,955,902 |  |  | $ | (789,322) |  |  | $ | (879,498) |  |  | $ | 403,117 |  |  | $ | 2,690,199 |
| 2022 |  | $ | 11,751,514 |  |  | $ | 3,365,229 |  |  | $ | (289,102) |  |  | $ | 441,169 |  |  | $ | 15,268,810 |
| 2021 |  | $ | 4,989,853 |  |  | $ | 1,461,574 |  |  | $ | 271,571 |  |  | $ | 315,938 |  |  | $ | 7,038,936 |
| 2020 |  | $ | 2,488,166 |  |  | $ | (365,446) |  |  | $ | 269,145 |  |  | $ | 204,866 |  |  | $ | 2,596,731 |
Compensation Actually Paid vs. Total Shareholder Return [Text Block] |  | Compensation Actually Paid Versus TSR 2020 – 2023 |  |  |
Compensation Actually Paid vs. Net Income [Text Block] |  | Compensation Actually Paid Versus Net Income 2020 – 2023 |  |  |
Compensation Actually Paid vs. Company Selected Measure [Text Block] |  | Compensation Actually Paid Versus Net Revenue 2020 – 2023 |  |  |
Total Shareholder Return Vs Peer Group [Text Block] |  | Compensation Actually Paid Versus TSR 2020 – 2023 |  |  |
Tabular List [Table Text Block] |  | ##### Financial Performance Measures As described in greater detail in “Executive Compensation – Compensation Discussion and Analysis” on page 45, our executive compensation program reflects a pay-for-performance philosophy, with a focus not only on the successful progression of research programs, clinical trials and the launch of new products but also on performance across a range of shorter-term metrics that advance our long-term strategy and longer-term value creation for our stockholders. The metrics that we use for both our long-term and short-term incentive awards are selected based on an objective of incentivizing our NEOs to increase the value of our company for our stockholders. As required by Item 402(v), the most important financial performance measures used by the Company to link executive compensation actually paid to the NEOs, for the most recently completed fiscal year, to the Company’s performance are as follows:
| a. | Net Product Revenue
| b. | Relative TSR
| c. | Non-GAAP Operating Income
Total Shareholder Return Amount | [3] | $ 147 | 150 | 121 | 93
Peer Group Total Shareholder Return Amount | [4] | 119 | 114 | 126 | 126
Net Income (Loss) Attributable to Parent | [5] | $ 5,613,000,000 | $ 4,566,000,000 | $ 6,201,000,000 | $ 89,000,000
Company Selected Measure Amount | [6] | 26,934,000,000 | 26,982,000,000 | 27,008,000,000 | 24,355,000,000
PEO Name |  | Mr. O’Day | Mr. O’Day | Mr. O’Day | Mr. O’Day
Measure [Axis]: 1 |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Measure Name |  | Net Product Revenue |  |  |
Measure [Axis]: 2 |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Measure Name |  | Relative TSR |  |  |
Measure [Axis]: 3 |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Measure Name |  | Non-GAAP Operating Income |  |  |
PEO [Member] | Less: Summary Compensation Table Reported Value of Equity Awards |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Adjustment to Compensation Amount | [7] | $ 15,615,056 | $ 14,353,915 | $ 13,139,064 | $ 11,513,097
PEO [Member] | Plus: Equity Award Adjustments |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Adjustment to Compensation Amount | [8] | 8,491,149 | 47,697,917 | 25,394,946 | 8,632,324
PEO [Member] | Year End Fair Value of Equity Awards Granted during the Year |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Adjustment to Compensation Amount |  | 12,525,814 | 34,153,918 | 17,162,219 | 8,885,442
PEO [Member] | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Adjustment to Compensation Amount |  | (2,481,113) | 14,183,571 | 6,011,125 | (1,693,496)
PEO [Member] | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Adjustment to Compensation Amount |  | (2,859,625) | (1,966,582) | 707,262 | 409,911
PEO [Member] | Value of Dividend Equivalents Accrued or other Earnings Paid on Stock Awards not Otherwise Reflected in Fair Value |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Adjustment to Compensation Amount |  | 1,306,073 | 1,327,010 | 1,514,340 | 1,030,467
PEO [Member] | Total Equity Award Adjustments |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Adjustment to Compensation Amount |  | 8,491,149 | 47,697,917 | 25,394,946 | 8,632,324
Non-PEO NEO [Member] | Less: Summary Compensation Table Average Reported Value of Equity Awards |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Adjustment to Compensation Amount |  | 4,809,225 | 4,961,052 | 3,625,534 | 3,087,064
Non-PEO NEO [Member] | Plus: Average Equity Award Adjustments |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Adjustment to Compensation Amount | [9] | 2,690,199 | 15,268,810 | 7,038,936 | 2,596,731
Non-PEO NEO [Member] | Average Year End Fair Value of Equity Awards Granted during the Year |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Adjustment to Compensation Amount |  | 3,955,902 | 11,751,514 | 4,989,853 | 2,488,166
Non-PEO NEO [Member] | Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Adjustment to Compensation Amount |  | (789,322) | 3,365,229 | 1,461,574 | (365,446)
Non-PEO NEO [Member] | Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Adjustment to Compensation Amount |  | (879,498) | (289,102) | 271,571 | 269,145
Non-PEO NEO [Member] | Average Value of Dividend Equivalents Accrued or other Earnings Paid on Stock Awards not Otherwise Reflected in Fair Value |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Adjustment to Compensation Amount |  | 403,117 | 441,169 | 315,938 | 204,866
Non-PEO NEO [Member] | Total Average Equity Award Adjustments |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
Adjustment to Compensation Amount |  | 2,690,199 | 15,268,810 | 7,038,936 | 2,596,731
Mr. O'Day |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |
PEO Total Compensation Amount | [10] | 22,607,690 | 21,621,253 | 19,229,466 | 18,998,095
PEO Actually Paid Compensation Amount | [11] | $ 15,483,783 | $ 54,965,255 | $ 31,485,348 | $ 16,117,322
[1] | The dollar amounts reported represent the average of the amounts reported for our NEOs as a group (excluding our CEO) in the “Total” column of the Summary Compensation Table in each applicable year. The NEOs included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2023 and 2022, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Deborah H. Telman; and (ii) for 2021 and 2020, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Brett A. Pletcher.
[2] | The dollar amounts reported represent the average amount of “compensation actually paid” to the NEOs identified in footnote 3, as computed in accordance with SEC rules. The dollar amounts do not reflect the actual amount of compensation earned by or paid to the any NEO during the applicable year. In accordance with the SEC rules, the following adjustments were made to average total compensation for the NEOs for each year to determine the compensation actually paid:
[3] | Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end of each year shown and the beginning of the measurement period by our share price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is December 31, 2019.
[4] | The peer group used for this purpose is Nasdaq Biotechnology Index.
[5] | The dollar amounts reported represent the amount of net income reflected in our Consolidated Statements of Income included in our Annual Report on Form 10-K for the applicable year. Included in our net income for 2020 was a $4.5 billion charge to acquired in-process research and development (“IPR&D”) expense recorded in connection with our acquisition of Forty Seven, Inc. Our 2022 net income included a $2.7 billion partial impairment charge related to certain IPR&D assets acquired from Immunomedics, Inc.
[6] | The dollar amounts reported represent the amount of net product sales revenue reflected in our Consolidated Statements of Income included in our Annual Report on Form 10-K for the applicable year. Total full year 2023 product sales of $26.9 billion were relatively flat compared to the same period in 2022, with lower Veklury sales largely offset by higher HIV and Oncology sales. Total product sales, excluding Veklury, increased 7% to $24.7 billion in the full year 2023 compared to 2022, primarily driven by higher HIV and Oncology sales.
[7] | Represents the aggregate grant-date fair value of equity awards as reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year.
[8] | The equity award adjustments for each applicable year were as set forth in the table below. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows:
[9] | The amounts deducted or added in calculating the total average equity award adjustments are as follows:
[10] | The dollar amounts reported are the amounts reported in the “Total” column of the Summary Compensation Table for our Chairman and Chief Executive Officer, Mr. O’Day.
[11] | The dollar amounts reported represent the amount of “compensation actually paid”, as computed in accordance with SEC rules, for Mr. O’Day. The dollar amounts do not reflect the actual amount of compensation earned by or paid during the applicable year. In accordance with SEC rules, the following adjustments were made to total compensation to determine the compensation actually paid:

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7 Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=3
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=gild_LessSummaryCompensationTableReportedValueOfEquityAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=gild_PlusEquityAwardAdjustmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=gild_YearEndFairValueOfEquityAwardsGrantedDuringTheYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=gild_YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=gild_YearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=gild_ValueOfDividendEquivalentsAccruedOrOtherEarningsPaidOnStockAwardsNotOtherwiseReflectedInFairValueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=gild_TotalEquityAwardAdjustmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=gild_LessSummaryCompensationTableAverageReportedValueOfEquityAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=gild_PlusAverageEquityAwardAdjustmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=gild_AverageYearEndFairValueOfEquityAwardsGrantedDuringTheYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=gild_AverageYearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=gild_AverageYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=gild_AverageValueOfDividendEquivalentsAccruedOrOtherEarningsPaidOnStockAwardsNotOtherwiseReflectedInFairValueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=gild_TotalAverageEquityAwardAdjustmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=gild_MrODayMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |